SI-BONE, Inc. (NASDAQ:SIBN) Stock Position Lifted by Barclays PLC

Barclays PLC lifted its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 190.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 96,623 shares of the company’s stock after purchasing an additional 63,402 shares during the quarter. Barclays PLC’s holdings in SI-BONE were worth $1,350,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of SIBN. Bank of New York Mellon Corp increased its stake in SI-BONE by 9.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 142,106 shares of the company’s stock valued at $1,837,000 after buying an additional 12,158 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of SI-BONE by 24.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock valued at $138,000 after acquiring an additional 2,108 shares in the last quarter. Rhumbline Advisers increased its stake in shares of SI-BONE by 1.5% during the second quarter. Rhumbline Advisers now owns 59,419 shares of the company’s stock valued at $768,000 after acquiring an additional 852 shares during the period. VELA Investment Management LLC raised its holdings in SI-BONE by 46.7% during the second quarter. VELA Investment Management LLC now owns 112,088 shares of the company’s stock worth $1,449,000 after purchasing an additional 35,674 shares in the last quarter. Finally, Arizona State Retirement System lifted its position in SI-BONE by 9.0% in the second quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock worth $141,000 after purchasing an additional 903 shares during the period. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Price Performance

NASDAQ SIBN opened at $13.72 on Friday. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $21.64. The business’s fifty day moving average is $13.46 and its two-hundred day moving average is $14.08. The stock has a market capitalization of $575.39 million, a P/E ratio of -14.91 and a beta of 1.20. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25.

Wall Street Analysts Forecast Growth

SIBN has been the topic of several research analyst reports. Truist Financial lifted their price target on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of SI-BONE in a report on Wednesday, November 20th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $23.00.

Insider Buying and Selling

In other SI-BONE news, insider Anthony J. Recupero sold 3,937 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.60, for a total transaction of $49,606.20. Following the completion of the sale, the insider now directly owns 228,554 shares of the company’s stock, valued at approximately $2,879,780.40. This represents a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Laura Francis sold 10,048 shares of SI-BONE stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.58, for a total transaction of $126,403.84. Following the completion of the transaction, the chief executive officer now directly owns 482,875 shares in the company, valued at approximately $6,074,567.50. This trade represents a 2.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,679 shares of company stock worth $276,439 in the last three months. 3.90% of the stock is currently owned by insiders.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.